Pertuzumab for the treatment of metastatic breast cancer.


Approximately 15% of primary breast cancers have amplification/overexpression of the cell surface receptor HER2. Despite the major improvements in survival achieved by the use of adjuvant trastuzumab, many of these patients still develop metastatic disease, and other patients with HER2 overexpressing breast cancer have overt metastases at first diagnosis… (More)
DOI: 10.1586/14737140.2013.814419


4 Figures and Tables